Developing Anti CD40LG Antibodies to Treat ALS

The immune system plays a key role in the progression of amyotrophic lateral sclerosis (ALS). Anelixis Therapeutics is developing monoclonal antibodies that block a specific immune system target expressed on lymphocytes (CD40LG) known to drive neurodegeneration. Anelixis Therapeutics is advancing a lead candidate AT-1501 into ALS clinical trials in 2018.